BENDITA BEnznidazole New Doses Improved Treatment and Associations

Summary

Recent scientific advances have provided further impetus to develop new therapeutic approaches for Chagas Disease (CD) using different doses and duration of BZN, as well as combinations directed at multiple therapeutic targets to improve treatment response and tolerability and reduce the potential for development of resistance. This project focuses on the proof-of-concept evaluation of improved treatment regimens of BZN, with the assessment of new BZN-sparing regimens in monotherapy and in combination with E1224.

Timeline

Start

2016-11-30

Primary completion

2018-01-28

Completion

2018-07-27

Publications

• Saade U, de Boer J, Scandale I, Altcheh J, Pottel H, Chatelain E, Zrein M. Early assessment of antibodies decline in Chagas patients following treatment using a serological multiplex immunoassay. Nat Commun. 2024 Dec 3;15(1):10530. doi: 10.1038/s41467-024-54910-x.
• Torrico F, Gascon J, Barreira F, Blum B, Almeida IC, Alonso-Vega C, Barboza T, Bilbe G, Correia E, Garcia W, Ortiz L, Parrado R, Ramirez JC, Ribeiro I, Strub-Wourgaft N, Vaillant M, Sosa-Estani S; BENDITA study group. New regimens of benznidazole monotherapy and in combination with fosravuconazole for treatment of Chagas disease (BENDITA): a phase 2, double-blind, randomised trial. Lancet Infect Dis. 2021 Aug;21(8):1129-1140. doi: 10.1016/S1473-3099(20)30844-6. Epub 2021 Apr 6.

Drugs

Indications